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Abstract: Oxidative stress is a key player of the inflammatory cascade responsible for the initiation
of ulcerative colitis (UC). Although the short chain quinone idebenone is considered a potent
antioxidant and a mitochondrial electron donor, emerging evidence suggests that idebenone also
displays anti-inflammatory activity. This study evaluated the impact of idebenone in the widely
used dextran sodium sulphate (DSS)-induced mouse model of acute colitis. Acute colitis was
induced in C57BL/6J mice via continuous exposure to 2.5% DSS over 7 days. Idebenone was
co-administered orally at a dose of 200 mg/kg body weight. Idebenone significantly prevented body
weight loss and improved the disease activity index (DAI), colon length, and histopathological score.
Consistent with its reported antioxidant function, idebenone significantly reduced the colonic levels
of malondialdehyde (MDA) and nitric oxide (NO), and increased the expression of the redox factor
NAD(P)H (nicotinamide adenine dinucleotide phosphate) dehydrogenase quinone-1 (NQO-1) in
DSS-exposed mice. Immunohistochemistry revealed a significantly increased expression of tight
junction proteins, which protect and maintain paracellular intestinal permeability. In support of an
anti-inflammatory activity, idebenone significantly attenuated the elevated levels of pro-inflammatory
cytokines in colon tissue. These results suggest that idebenone could represent a promising therapeutic
strategy to interfere with disease pathology in UC by simultaneously inducing antioxidative and
anti-inflammatory pathways.
Keywords: idebenone; cytokines; inflammatory bowel disease; lipid peroxidation; superoxide
dismutase; tight junction proteins and ulcerative colitis
1. Introduction
Inflammatory bowel disease (IBD) is characterised as a chronic, relapsing, multifactorial disorder
of the gastrointestinal tract with an unknown aetiology. It is primarily divided into two major
sub-forms: ulcerative colitis (UC) and Crohn’s disease (CD) [1]. IBD often presents with colonic or
extra-colonic manifestations, along with clinical symptoms of abdominal pain, diarrhoea, bloody
stools and weight loss. Both genetic susceptibilities and environmental factors lead to the initiation of
disease [1]. However, the exact underlying mechanisms are yet to be elucidated. Many studies implicate
a defective immune response, oxidative stress, altered barrier integrity and microbial dysbiosis of the
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gut in the pathogenesis of IBD [2]. Numerous animal models of IBD have utilised chemicals such as
dextran sodium sulphate (DSS), oxazolone, acetic acid and tri-nitrobenzene sulphonic acid (TNBS) to
investigate the molecular mechanisms of colitis. The potential of these preclinical models of colitis for
targeted therapy have been widely described [3–7].
The DSS mouse model is one of the well-established indispensable tools for studying intestinal
inflammation that recapitulates the morphological and clinical symptoms of human IBD, such as weight
loss, diarrhoea, rectal bleeding, shortening of the colon, depletion of goblet cells and ulcerations [8,9].
DSS is thought to exert its action by irritating the epithelium, which increases the permeability of
intestinal membranes by changing the expression of tight junction (TJ) proteins, such as zona-occludin
1 (ZO-1), occludin and claudins as early as day 1 of DSS administration [10–12]. These chronological
alterations lead to a defective mucosal defence, which results in infiltration of the immune cells and
release of pro-inflammatory cytokines [13,14]. Oxidative stress due to the overproduction and release
of reactive oxygen species (ROS) by macrophages and other immune cells also plays a fundamental
role in the pathophysiology of DSS-induced inflammation [15].
The imbalance between the levels of radicals and antioxidative enzymes contributes to oxidative
stress and initiates the peroxidation of fatty acids and lipoproteins in cell membranes. The end
product of lipid peroxidation (malondialdehyde) is highly toxic for cells and tissues [16]. In response to
oxidative stress, the redox-sensitive transcription factor nuclear factor erythroid 2-related factor 2 (Nrf-2)
initiates an antioxidant response by activating the expression of phase II detoxifying enzymes, such as
NAD(P)H quinone oxidoreductase 1 (NQO-1), hemeoxygenase 1 (HO-1) and superoxide dismutase
(SOD). This adaptive response is cytoprotective and enhances desensitisation against cytotoxicity and
oxidative damage. There is some evidence that activation of the Nrf-2/NQO-1 redox pathway via
pharmacological pre-conditioning can ameliorate DSS-induced inflammation in mice [17–19]. Current
treatment of ulcerative colitis with non-steroidal anti-inflammatory drugs (NSAIDS), allopurinol,
corticosteroids, immunosuppressant and biological agents show potential adverse effects, such as
steroid dependency and infections [20–23]. Given the need to develop new therapeutic approaches
to treat intestinal inflammation and oxidative damage, therapeutics that synergise antioxidant and
anti-inflammatory activities could be a promising approach for the treatment of UC.
The short-chain quinone idebenone is a potent antioxidant and mitochondrial electron donor [24].
Idebenone was developed by Takeda Pharmaceuticals for the treatment of dementia in the 1980s.
At present, it is marketed in Europe by Santhera Pharmaceuticals for the treatment of a rare
inherited mitochondrial disorder and trials are ongoing for neurodegenerative and neuromuscular
indications [25]. Idebenone is well tolerated and safe as either a single dose or multiple dose daily [26].
The related molecule MitoQ, a mitochondrial targeted derivative of idebenone, was previously
reported to ameliorate DSS-induced intestinal inflammation in mice [27]. In addition, in a rat model
of titanium-dioxide-induced kidney toxicity, idebenone reduced the malondialdehyde (MDA) levels;
the pro-inflammatory cytokines interleukins 1, 6 and tumor necrosis factor-alpha (IL-1, IL-6 and
TNF-α); and nitric oxide (NO) levels [28]. This reduction was associated with improvement in kidney
function. In a model of LPS (lipopolysaccharide)-induced neuro-inflammation, idebenone alleviated
the disease phenotype, which was associated with a reduction of pro-inflammatory cytokines, reduction
of inducible nitric oxide synthase (iNOS) and by maintaining the polarisation between M1 and M2
macrophages [29]. However, there is only limited information about the exact mechanism(s) of action
of idebenone. In vivo and in vitro evidence suggests that idebenone inhibits lipid peroxidation and
maintains the redox balance by scavenging free radicals, including peroxynitrite, superoxides and
peroxyls [30–35]. Furthermore, idebenone also interacts with the mitochondrial electron transport
chain and maintains cellular ATP production by transferring electrons to complex 3 of the electron
transport chain [36,37]. The effectiveness of idebenone depends on the two-electron reduction by the
cytoplasmic flavoprotein NQO-1, which also prevents the formation of unstable cytotoxic semi-quinone
radicals [38]. This reduction of idebenone limits the formation of superoxide radicals and contributes
to its antioxidative activity [39,40].
Int. J. Mol. Sci. 2020, 21, 484 3 of 21
We therefore hypothesised that idebenone might be a promising drug to alleviate DSS-induced
inflammation due to the combination of anti-inflammatory and antioxidant activities. The current study
demonstrated that idebenone successfully ameliorated intestinal inflammation and maintained tissue
redox homeostasis, which was associated with an upregulation of the antioxidant enzyme NQO-1.
2. Results
2.1. Idebenone Improved the Clinical and Macroscopic Features of Colitis
Administration of 2.5% DSS for 7 days (Figure 1A) replicated the early clinical symptoms of colitis
in mice, such as body weight loss, gross rectal bleeding and diarrhoea. In comparison with healthy
controls (HC) (4.48 ± 1.29%), DSS-treated animals continuously lost body weight until the end of the
experiment, i.e., till day 8 (−7.56 ± 1.67%) (Figure 1B). Under these conditions, idebenone effectively
prevented body weight loss (−2.74 ± 2.54%) in DSS-treated mice till day 8. The disease activity
index (DAI), calculated as a composite of occult faecal blood, stool consistency and body weight, was
significantly (p < 0.0001) increased in DSS-treated mice from day 2 onwards (Figure 1C). Idebenone
treatment significantly reduced the severity of disease symptoms as evidenced by improvements in
faecal blood and watery stools from day 7 (p < 0.05) until the end of the observation period on day 8
(p < 0.0001) compared to DSS-treated animals.
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Figure 1. Effect of idebenone on the pathology of dextran sodium sulphate (DSS)-induced experimental
colitis. (A) Experimental design for the administration of DSS and idebenone in C57BL/6J mice,
(B) % body weight change, (C) disease activity index (DAI) of healthy controls (HC), DSS and
DSS-plus-idebenone-treated mice (DSS + I). Statistical significance among the groups was evaluated
using two-way ANOVA followed by Tukey’s post-test, where * p < 0.05 and **** p < 0.0001 versus
DSS. Data are expressed as a mean ± SEM (n = 10/group). (D) Colon length and (E) macroscopic
appearance of colon as a mean ± SEM (n = 10/group), evaluated using one-way ANOVA followed by
Tukey’s post-test.
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DSS-induced inflammation significantly (p < 0.0001) shortened the colon length (5.25 cm ± 0.17),
in contrast with HC (7.09 cm ± 0.08). Consistent with the reduction in disease severity, idebenone
treatment significantly (p < 0.0001) normalised the colon length compared to DSS-treated animals
(6.46 cm ± 0.14) (Figure 1C,D). This data suggests a beneficial effect of idebenone treatment on the
clinical symptoms of experimental acute colitis.
2.2. Idebenone Reduced the Colon Histopathology in Acute Colitis
The histopathology of the proximal (PC) and distal colon (DC) was assessed using haematoxylin
and eosin (H&E) staining of tissue sections (Figure 2A). Colon tissues from the HC group displayed the
integrity of colonic mucosal structures without signs of inflammation. In contrast, DSS-treated mice
showed severe deterioration of crypts, loss of goblet cells, annihilation of epithelial cells, submucosal
oedema and massive infiltration of inflammatory cells. These DSS-induced changes were associated
with higher cumulative histology scores when compared to HC (Figure 2B,C) and affected the DC
(17.80 ± 0.75) more than the PC (9.40 ± 0.71) (Figure 2B). In DSS-treated mice, idebenone treatment
markedly protected against colonic inflammation in the DC by preventing intestinal injury and
significantly lessening the histology score (13.40 ± 1.18) (Figure 2C). Unlike its effect in the DC,
idebenone treatment showed no significant protection in the PC (6.70 ± 1.06) (Figure 2B).
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Figure 2. Effect of idebenone on histopathology in DSS-induced colitis. (A) Histological 
representation of proximal colon (PC) and distal colon (DC) sections stained with haematoxylin and 
eosin (H&E) for healthy controls (HC), DSS-treated mice (DSS) and DSS-plus-idebenone-treated mice 
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Figure 2. Effect of idebenone on histopat ol gy in DSS-i duced colitis. (A) Histological representation
of proximal colon (PC) and distal colon (DC) secti ns stained with haematoxylin and eosin (H&E) for
healthy controls (HC), DSS-treated mice (DSS) and DSS-plus-idebenone-treated mice (DSS + I) at 20×
magnification. (B,C) Histopathology scores for each animal calculated after microscopic analysis of
tissue sections from the PC and DC. Statistical significance among groups was evaluated using one-way
ANOVA followed by Tukey’s post-test, where ns denotes non-significance, ** p < 0.01 and **** p < 0.0001.
Data are expressed as a mean ± SEM (n = 10/group). Arrows indicate crypts/regeneration of crypts
(red), goblet cells (blue), epithelium surface erosion (black), inflammatory cells infiltration (white) and
submucosal oedema (yellow).
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2.3. Idebenone Preserved the Intestinal Barrier Integrity and Protected against Goblet Cell Loss in
DSS-Induced Colitis
Tight junction (TJ) proteins are essential for the maintenance of the intestinal epithelial barrier
that limits the entry of harmful molecules into the lamina propria. Therefore, the expression of TJ
proteins occludin and ZO-1 was assessed using immunohistochemistry. In HC, occludin and ZO-1
were expressed homogenously and were mainly detected around the surface membrane and around
the crypts (Figure 3A) of the epithelium. However, in response to DSS, the colonic barrier integrity
and crypt structure was severely affected, resulting in the low expression of TJ proteins (Figure 3A).
In contrast, idebenone treatment preserved and maintained the intestinal barrier integrity, which was
associated with high expression levels of occludin and ZO-1 (Figure 3B,C) along the epithelial cell
membrane and intact colonic crypts (Figure 3A).
Int. J. Mol. Sci. 2020, 21, x 5 of 21 
 
crypts/regeneration of crypts (red), goblet cells (blue), epithelium surface erosion (black), 
inflammatory cells infiltration (white) and submucosal oedema (yellow). 
2.3. Idebenone Preserved the Intestinal Barrier Integrity and Protected against Goblet Cell Loss in DSS-
Induced Colitis 
Tight junction (TJ) proteins are essential for the maintenance of the intestinal epithelial barrier 
that limits the entry of harmful molecules into the lamina propria. Therefore, the expression of TJ 
proteins occludin and ZO-1 was assessed using immunohistochemistry. In HC, occludin and ZO-1 
were expressed homogenously and were mainly detected around the surface membrane and around 
the crypts (Figure 3A) of the epithelium. However, in response to DSS, the colonic barrier integrity 
and crypt structure was severely affected, resulting in the low expression of TJ proteins (Figure 3A). 
In contrast, idebenone treatment preserved and maintained the intestinal barrier integrity, which was 
associated with high expression levels of occludin and ZO-1 (Figure 3B,C) along the epithelial cell 
membrane and intact colonic crypts (Figure 3A). 
Alcian blue staining was performed to quantify the mucus level in the intestinal goblet cells. 
Consistent with a general protective effect, idebenone significantly (p < 0.05) increased mucus levels 
co pared to the reduced mucus levels in DSS-treated animals (Figure 4).  
 
Figure 3. Effect of idebenone on tight junction protein expression in DSS-induced experimental colitis. 
(A) Immunohistochemical analysis of occludin and zona-occludin 1 (ZO-1), (B) average occludin 
expression in the distal colon and (C) average ZO-1 expression in the distal colon. Data are expressed 
Figure 3. Effect of idebenone on tight junction protein expression in DSS-induced experimental colitis.
(A) Immunohistochemical analysis of occludin and zona-occludin 1 (ZO-1), (B) average occludin
expression in the distal colon and (C) average ZO-1 expression in the distal colon. Data are expressed
as a mean ± SEM (n = 3/group) and statistical significance was evaluated using one-way ANOVA
followed by Tukey’s post-test, where ** p < 0.01, ***p < 0.001 and **** p < 0.0001. Images are at 40×
magnification. Arrow indicates the localization of staining.
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Alcian blue staining was performed to quantify the mucus level in the intestinal goblet cells.
Consistent with a general protective effect, idebenone significantly (p < 0.05) increased mucus levels
compared to the reduced mucus levels in DSS-treated animals (Figure 4).
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Figure 4. Effect of idebenone on goblet cell loss in colitis. Goblet cells producing mucus stained with
alcian blue dye for HC, DSS and DSS + I groups in the distal colon, along with a graphical representation
of the staining intensity of alcian blue dye for each group (n = 3/group). Statistical significance among
groups was evaluated using one-way ANOVA followed by Tukey’s post-test, where * p < 0.05 and
*** p < 0.001. Images are at 40×magnification.
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Figure 5. Effect of idebenone on oxidative stress in DSS-induced colitis. (A) Malondialdehyde (MDA)
levels in the distal colon, (B) total superoxide dismutase (SOD) activity in the distal colon expressed
as a percentage inhibition rate of reduction of xanthine oxidase activity and (C) nitric oxide (NO)
concentration (µM)/gram in distal colon tissue. Data are expressed as a mean ± SEM (n = 3/group).
Statistical significa ce among groups was evaluated using one-way ANOVA followed by Tukey’s
post-test, where * p < 0.05, ** p < 0.01 and *** p < 0.001.
2.5. Idebenone Upregulated the Expression of the Phase II Detoxifying Enzyme NQO-1
As another readout of an Nrf-2-driven antioxidant response, the tissue levels of NQO-1 were
assessed in the test animals using western blotting. While DSS exposure itself did not affect NQO-1
protein levels, idebenone up-regulated NQO-1 protein in the DSS-treated mice (Figure 6A). When
the subcellular localisation of NQO-1 was assessed using immunohistochemistry, NQO-1 was mainly
expressed in the cytoplasm of pithelial cells in healthy animals (Figure 6B). In contrast, in t
DSS-exposed nim ls, only a diffuse expression of NQO-1 aro d the lamina propria was detected
(Figur 6B). Idebenone treat ent signific ntly increased the expression of NQO-1 in the l mina propria
(p < 0.05 vs. DSS) (Figure 6B).
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2.6. Idebenone Reduced the Levels of Pro-Inflammatory Cytokines in Colon Tissue
DSS-induced inflammation is associated with the release of an array of pro-inflammatory cytokines.
To investigate the anti-inflammatory effects of idebenone, the colon tissue levels of pro-inflammatory
cytokines and chemokines were quantified in the test animals. In the distal colon (DC), idebenone
consistently downregulated the levels of IL-1α, IL-6, TNF-α, GM-CSF (granulocyte macrophage colony
stimulating factor), G-CSF (granulocyte colony stimulating factor), IL-17, IL-10 and IL-3 (Figure 7A).
In addition, idebenone also significantly lowered the levels of chemokines MIP-1α (macrophage
inflammatory protein 1 alpha), MIP-1β (macrophage inflammatory protein 1beta), RANTES (Regulated
on Activation, Normal T Expressed and Secreted) and eotaxin in the DC (Figure 7A). In the proximal
colon (PC), idebenone significantly reduced IL-6, TNF-α, GM-CSF, MIP-1α, IL-10 and IL-17 in the PC
(Figure 7B). Thus, in line with its protective activity, the immunomodulatory effects of idebenone were
more prominent in the DC compared to the PC. No significant effects were detected for several other
cytokines (Supplementary Figure S1).
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Figure 7. Effect of idebeno e on the level -infla mator cytokines and chemokines in colon
tissue. (A) Tissue levels of interleukin (IL)-1α, IL-6, tumour necrosis factor alpha (TNF-α), macrophage
inflammatory protein 1 alpha (MIP-1α), MIP-1β, granulocyte colony stimulating factor (G-CSF),
granulocyte macrophage CSF (GM-CSF), RANTES, eotaxin, IL-10, IL-17 and IL-3 in the distal colon
and (B) the levels of IL-6, TNF-α, GM-CSF, eotaxin and IL-17 in the proximal colon were quantified
using a Bio-Plex assay. Data are expressed as a mean ± SEM (n = 3/group) and statistical significance
was evaluated using one-way ANOVA followed by Tukey’s post-test, where * p < 0.05, ** p < 0.01 and
*** p < 0.001.
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3. Discussion
For the first time, the current study revealed a protective role for idebenone in a well-described
and frequently used pre-clinical murine model of acute colitis. Our results demonstrate the substantial
therapeutic potential of idebenone in reducing the severity of DSS-induced disease by simultaneously
exerting both antioxidant and anti-inflammatory activities, while concomitantly regulating the immune
responses and barrier function.
The current study used idebenone at a dose of 200 mg/kg that previously ameliorated oxidative
stress, pro-inflammatory cytokines and DNA damage in a titanium-dioxide-induced hepatotoxicity
model [41], and also improved cardiac function [42]. Since administration of idebenone with food
is known to increase its bioavailability by 5 to 7 times [43], idebenone was administered with chow
pellets in the present study. It must be acknowledged that the present study did not approach the
question of finding an optimal drug dose, which should be included in future studies. However,
based on the Food and Drug Administration (FDA)-approved conversion factor between mouse
and men [44], 200 mg/kg/day in mice would translate to a dose of less than 1.2 g/day (based on
a 70 kg patient body weight). Idebenone at doses of up to 2250 mg/day are considered safe and
tolerable for human administration [26], which places the dose used in the current study into a possible
therapeutic range that could be used in clinical trials. Although high idebenone doses can cause
gastro-intestinal-related adverse effects, such as vomiting, dyspepsia and mild-to-moderate diarrhoea
in patients [45], the present study did not observe any gastro-intestinal-related adverse effects. Instead,
idebenone significantly improved the body weight, DAI and histopathology. Our results support the
previously reported involvement of oxidative stress in the pathogenesis of disease [15] and justify the
use of antioxidants to alleviate structural tissue damage [19,27,46,47].
It is well established that reactive oxygen species and reactive nitrogen species (RNS) at low
concentrations and over short time intervals are essential signalling molecules involved in a multitude
of physiological processes [48]. However, when cells are exposed to elevated levels of ROS and the
subsequent lipid peroxidation over longer time periods, they are unable to cope with the oxidative
damage that can disrupt cell and tissue functions in the gastrointestinal tract [16]. It is therefore
thought that strengthening the antioxidant defence machinery counteracts the harmful effects of ROS
in the body. In this context, one of the major events in the cellular response to oxidative stress is
mediated by the activation of phase II detoxifying enzymes NQO-1 and SOD [49]. The antioxidants
SOD and NQO-1 directly eliminate free superoxide radicals to protect against lipid peroxidation [50,51].
Previous reports of acute gut inflammation in the DSS model observed a significant increase in lipid
peroxidation and reduced levels of antioxidant enzymes (NQO-1 and SOD) [18,19,52–56], which were
replicated in the present study. We also observed a significant reduction in MDA levels after treatment
with idebenone, which is consistent with a previous report where idebenone effectively suppressed
lipid peroxidation in brain mitochondria [57]. In line with the activation of an endogenous defence
mechanism, idebenone increased the NQO-1 expression and SOD activity rate in our study (Figure 6).
Previous reports associated elevated levels of NO with the severity of colitis in UC patients and in
animal models [58–60]. In line with idebenone-dependent protection, idebenone also influenced RNS
by reducing NO levels in our study. These results indicate that idebenone protects mucosal injury by
strengthening the antioxidant defence machinery.
However, it must be noted that idebenone has also been associated with a pro-oxidative activity
in some reports [61], which appears counterintuitive given the abundance of its antioxidant effects.
Idebenone, like all quinones, can be reduced by a single electron reduction to the unstable semiquinone,
which can give rise to oxidative radicals [62]. This reaction is effectively suppressed by NQO-1 through
a competing two-electron reduction to the hydroquinone. Therefore, cells and tissues with low or
absent NQO-1 levels are at risk of semiquinone-induced oxidative stress. It is therefore possible that
low levels of semiquinones could trigger increased NQO-1 expression in an Nrf2-dependent manner to
counteract quinone-induced oxygen radicals until at higher NQO-1 concentrations, where idebenone
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is fully reduced to the hydroquinone to exert its antioxidant activity. More detailed studies will be
required to investigate this theoretical possibility.
The accumulation of ROS and RNS also disrupt the intestinal barrier integrity by redistributing
TJ protein complexes involving occludin and ZO-1, which leads to a vicious cycle of intestinal
inflammation [63–70]. Therefore, restoring barrier integrity to mediate the resolution of
pro-inflammatory responses could be a beneficial strategy in the treatment of UC. In this regard,
idebenone was previously reported to decrease the permeability of the blood–brain barrier by
up-regulating occludin and ZO-1 proteins in a rat model of diabetes [71]. Likewise, our results in the
colitis model also suggest that idebenone protected the expression of TJ proteins and preserved the
integrity of the epithelial barrier. The substantial loss of TJ proteins in the DSS-treated mice in the
present study mirrored previous reports [72,73]. However, it is unclear whether idebenone increased
the expression of the TJ proteins or protected against their DSS-dependent degradation. Moreover, the
present study also demonstrated a significant protection of goblet cells by idebenone. The loss of goblet
cells upon DSS induction replicates the depletion of goblet cells in UC patients and rodents [72,74].
Indeed, this is the first study that shows a protective effect by idebenone against intestinal goblet cell
loss. However, to understand the detailed molecular mechanism(s) for this effect, further detailed
investigations will be required.
Gut inflammation is characterised by the overproduction of pro-inflammatory cytokines and
chemokines, along with altered barrier integrity and an oxidative response [14,16,69,75]. Activation of
neutrophils and macrophages in the lamina propria during mucosal injury result in inflammation via
the aberrant secretion of cascades of pro-inflammatory cytokines [76]. DSS-induced acute colitis is a
macrophage/Th1/Th17 driven inflammatory mouse model with elevated levels of cytokines including
TNF-α (a hallmark of DSS-induced inflammation), IL-6, IL-1β and IL-17 [77–80]. Therefore, suppression
of pro-inflammatory cytokines is thought to represent an essential part of the therapeutic approach
against UC. Evidence for idebenone-induced anti-inflammatory activity was previously proposed
in a rat model of titanium-dioxide-induced renal damage and in LPS-induced neuro-inflammation
in BV2 microglial cells that involved the suppression of IL-1β, TNF-α and IL-6 [28,29]. Our results
illustrate a substantial suppression of the pro-inflammatory cytokines IL-1α, TNF-α, IL-6 and IL-17
to their baseline levels by idebenone (Figure 7). In addition, idebenone also reduced the levels of
GM-CSF, G-CSF and IL-3, which are responsible for the differentiation and recruitment of monocytes
to macrophages into the lamina propria during intestinal inflammation [81].
It is well known that the anti-inflammatory cytokine IL-10 is elevated in colitis patients [47,82–86]
and our study mirrored this effect upon DSS exposure. Elevated levels of IL-10 could be interpreted as
a compensatory mechanism to counteract the substantial inflammation in the colon. In the context of a
reduced pro-inflammatory response by idebenone, a reduction of IL-10 levels in the present study does
therefore not appear surprising.
Our results also align with clinical studies that reported up-regulated chemokines, such as MIP-1α,
MIP-1β, eotaxin and RANTES, in the colonic biopsies of UC patients [49,83,87–89]. However, profound
effects were seen in our study where idebenone down-regulated the release of these chemokines in the
DSS-treated mice. The significant reduction of pro-inflammatory cytokine levels by idebenone could be
either a direct immunomodulatory effect or indirectly reflective of a general protection of antioxidant
enzymes and/or barrier integrity. Since macrophages seem to play a vital role in colitis through
the production of many cytokines [81,90], detailed studies will be required to elucidate the effect of
idebenone on macrophages and to identify the functional links between ROS and cytokine levels.
Apart from DC, idebenone administration also showed significant reductions of IL-6, TNF-α,
GM-CSF, MIP-1α, eotaxin and IL-17 in the PC. Our results also indicated that the inflammation level
varied between PC and DC. This has been substantiated by previous studies [49,72,83], where the DC
of DSS controls showed more histological destructions than the PC.
Very few randomised controlled clinical trials have reported therapeutic effects of antioxidants
in UC patients. Trials that tested compounds, such as curcumin and polyunsaturated fatty acids
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(PUFAs), were associated with methodical limitations, including short duration, small subject size
or the absence of a healthy control group [91,92]. Other studies that investigated compounds such
as resveratrol, carnosine and ferrous fumarate were insufficiently sized to show any therapeutic
benefits. Moreover, some antioxidants showed better efficacy when given in combination with other
compounds, and mixed treatment outcomes were reported as being influenced by the antioxidant
potency, dosage, stage of disease and duration [93–97]. Therefore, at present, it is not possible to
align the multiple contradicting results of the reported clinical trials. On the other side, a plethora of
literature supports the role of oxidative stress in UC and consequently justifies the use of antioxidants
as a therapeutic strategy [15,27,52,54,60,98–102]. Since UC is a multifactorial disease, pharmacological
targeting of individual factors appears of limited use to provide effective and sustainable therapy
outcomes. In contrast, the present study highlighted that idebenone appeared to target not only one,
but multiple factors relevant to UC that included the barrier integrity, mucus production, oxidative
stress and inflammatory markers (Figure 8). It is intriguing to speculate that it was the synergistic effect
of these activities that could be responsible for the significantly reduced severity of colitis observed in
this study.
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SS-induced acute colitis. Induction of DSS disrupts tight junctions (Z -1 and occludin) and the
ucus fil covering epithelial cells, resulting in the increased infiltration of har ful icrobes and
toxins into the la ina propria. This uptake activates acrophages, neutrophils and ly phocytes,
ca sing disse ination of pro-inflammatory cytokines (IL-6, IL-1a, TNF-a, IL-17, IL-3, GM-CSF and
G-CSF), chemokines and generates oxidative and nitrosative stress (free radicals and NO). In colitis,
NO is released by immune cells, as well as by IECs, which further damages tight junctions. All these
factors contribute to the inflammation of the colon. Increased levels of oxidative stress via altered
redox levels between oxidative molecules and anti-oxidative enzymes (NQO-1 and SOD) damages
tissue and cells through oxidative damage to macromolecules, including lipids. Supplementation
with idebenone maintains the barrier integrity by protecting tight junctions and the mucin layer.
Idebenone also supresses the pro-inflammatory cytokines, chemokines, NO production and LPO. In
addition, by increasing the levels of detoxifying enzyme NQO-1 and SOD, idebenone is thought to
prevent colonic inflammation by simultaneously protecting against oxidative stress and inflammation.
IECs—intestinal epithelial cells, G-CSF—granulocyte colony stimulating factor, GM-CSF—granulocyte
macrophage colony stimulating factor, IL—interleukin, LPO—lipid peroxidation, NO—nitric oxide,
NQO-1—NAD(P)H dehydrogenase quinone 1, SOD—superoxide dismutase, TNF-α—tumor necrosis
factor alpha and ZO-1—zona occludin 1.
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Accumulation of oxidative stress not only damages the colon, but also stimulates the release of
pro-inflammatory cytokines and increases intestinal permeability. It must be noted that at present,
it is still unclear how the different idebenone-dependent events that protect against colitis are
initiated and regulated, and whether there is a functional or temporal hierarchy between the different
activities described in the current study. To our knowledge, the present study is the first to explore
the antioxidative and anti-inflammatory properties of idebenone in attenuating the pathology of
acute colitis. Idebenone provides effective cytoprotection against oxidative damage, likely by a
SOD/NQO-1-dependent mechanism, maintaining intestinal barrier function and simultaneously
preventing the up-regulation of pro-inflammatory cytokines in a mouse model of DSS-induced acute
colitis. Therefore, our study strongly suggests that idebenone could be developed as a promising
therapeutic alternative to treat the acute phases of UC.
4. Material and Methods
4.1. Animals
All female C57BL/6J mice were purchased from the University of Tasmania animal breeding
facility. Mice were caged individually with access to standard chow and autoclaved drinking water ad
libitum. Animals were housed at a controlled temperature with 12-h day/night light cycle. Individual
body weights were assessed daily over an acclimatisation period of 7 days before being included into
any experiments. All procedures were approved by the Animal Ethics Committee of University of
Tasmania (ethics approval number: A0016166 and approval date:6th March 2017. Experiments were
conducted according to the Australian code of practise for the care and use of animals for scientific
purposes (8th edition 2013).
4.2. Experimental Design and Drug Treatment
Female C57BL/6J mice aged 6–7 weeks with an average weight around 18 g were randomly
divided into three groups (n = 10/group): healthy controls without DSS and drug (HC), DSS treatment
(DSS) and DSS + idebenone treatment (DSS + I). All animals were acclimatised for 1 week before
the start of the experiment. Colitis was induced by administering 2.5% DSS (molecular weight –
30,000-50,000 KDa) (MP Biomedicals, New South Wales, Australia) in autoclaved drinking water to all
groups except HC, continuously over 7 days. Idebenone was prepared as wet food mash by mixing
it with 0.5% of carboxymethylcellulose (CMC), 4% sucrose and autoclaved powdered chow pellets.
Idebenone was administered orally at a dose of 200 mg/kg of body weight. HC were supplied with
normal autoclaved water and standard autoclaved chow pellets in the form of food mash. DSS-treated
and DSS + idebenone groups were treated with a drug vehicle and idebenone (200 mg/kg of body
weight), respectively, for the treatment period of 7 days. Food mash was aliquoted as 2.5 g per dish
and was stored at −20 ◦C until use.
4.3. Clinical and Histopathological Evaluations
The disease activity index (DAI) was calculated as the sum of the individual scores for bloody
stool, stool consistency and body weight loss, as previously described [72,103]. All three parameters
were recorded daily over 7 days until the end of the experiment on day 8. In brief, scores were
determined as follows: stool consistency (0 = normal, 1 = semi-formed, 2 = very soft/loose stool,
3 = diarrhoea or watery stool), bloody stool (0 = no blood/negative haemoccult, 1 = positive haemoccult,
2 = visible blood traces, 3 = gross bleeding) and body weight loss (0 = 0%, 1 = 1–5%, 2 = 6–10%,
3 = 11–15%). After dissecting the mice on day 8, the colons were taken out and the lengths were
recorded. The colon was opened and longitudinally cut into two halves. One-half was collected for
histopathological evaluations using the Swiss roll technique and another half was snap-frozen for
further molecular assays. The Swiss roll was then fixed in 10% neutral formalin buffer and embedded
in paraffin. Paraffin-embedded tissue slides were stained with haematoxylin and eosin (H&E) staining
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and histopathological scoring was done in a blinded manner, as described previously [104]. Images
were captured using a Leica DM500 microscope (Leica Microsystems, Mannheim, Germany).
4.4. Immunohistochemistry
An HRP/DAB detection IHC kit from Abcam (ab64261, Abcam, Victoria, Australia) was used
to perform immunohistochemical analysis, as previously described [49]. Briefly, paraffin-embedded
tissues were sectioned into 5-µm slices, were dewaxed in xylene and then rehydrated in a series
of graded ethanol (100%, 100%, 95% and 70%). Slides were then incubated for antigen retrieval at
121 ◦C for 4 min using a citrate buffer (pH 6) in a decloaking chamber. After washing in phosphate
buffered saline (1× PBS), slides were incubated with a hydrogen peroxide block in order to block
endogenous peroxidase activity for 10 min, followed by protein blocking for 30 min at room temperature.
Subsequently, slides were incubated overnight at 4 ◦C with primary antibodies against occludin (1:600)
(NBP1-87402, Novus Biologicals, Victoria, Australia), ZO-1 (1:400) (NBP1-85046, Novus Biologicals)
and NQO-1 (1:400) (ab34173, Abcam). After washing the slides in PBS, slides were incubated with
biotinylated goat anti-rabbit IgG and Streptavidin-peroxidase conjugate for 10 min each according
to the manufacturer’s instructions (Abcam). Finally, slides were incubated with DAB chromogen
(3,3′-diaminobenzidine) and substrate for 10 min. Tissues were counterstained using haematoxylin
before being mounted with DPX medium (Sigma-Aldrich, New South Wales, Australia). Images were
captured using a Leica DM500 microscope and Image Pro-Plus 7 software (Media Cybernetics, Inc.,
Rockville, MD, USA) to analyse the staining intensity by randomly choosing four different fields per
slide (n = 3/group), with the observer being blinded to the diagnosis.
4.5. Western Blotting
Briefly, distal colon tissue sections were homogenised and lysed in a RIPA buffer containing
protease inhibitor cocktails (Complete ULTRA Tablets, Mini, EDTA-free, Roche, New South wales,
Australia). Protein quantification was done using a DC protein Assay Kit from Biorad. The samples
were suspended in loading dye and boiled at 95 ◦C for 5 min. A total of 20 µg of protein was separated
on 4–15% of SDS-PAGE gel (Mini-PROTEAN TGX Precast Gels (50 µL), Biorad, New South Wales,
Australia) at 100 V for 60 min, then electro-transferred to a PVDF membrane at 250 A for 60 min.
The membranes were blocked with 5% non-fat milk for 1 h at room temperature (RT) and then incubated
with primary antibodies against NQO-1 (1:1000) (ab34173, Abcam) and β-actin (1:8000) (NB600-503,
Novus Biologicals) overnight at 4 ◦C. After washing, membranes were incubated with horseradish
peroxidase (HRP)-conjugated secondary antibody (1:3000, 7074, Cell Signaling Technology, Australia)
for 1 h at RT. The bands were visualised with a chemiluminescence reagent (SuperSignal, West Pico
PLUS, Chemiluminescent Substrate, Thermo Scientific, Victoria, Australia) and imaged using a Fujifilm
Luminescent Image Analyzer (LAS-3000 image reader, version 2.2) (Fuji Life Sciences, Japan).
4.6. Alcian Blue Staining
Alcian blue staining kit (ab150662 Alcian Blue stain kit, pH 2.5 (Mucin Stain), Abcam, Australia)
was utilised to visualise the sulphated and acidic mucopolysaccharides (MUC2). Staining was
performed as described previously [105]. Briefly, paraffin-embedded slides were dewaxed in xylene
and rehydrated in a series of graded ethanol. Slides were incubated with alcian blue for 30 min at
RT. Slides were counterstained with Safranin O for 5 min, dehydrated and cleared in xylene before
mounting with DPX medium. Images were captured using a Leica DM500 microscope and Image
Pro-Plus 7 software (Media Cybernetics, Inc., Rockville, Maryland, United States of America) was used
to analyse the staining intensity by randomly choosing four different fields per slide (n = 3/group),
with the observer being blinded to the diagnosis.
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4.7. Lipid Peroxidation Assay
The levels of MDA as a marker of lipid peroxidation was determined by using a commercially
available lipid peroxidation colorimetric/fluorometric assay kit (K739, Bio Vision, New South Wales,
Australia), as mentioned previously [106]. Briefly, the distal colon tissue was homogenised with a lysis
buffer and centrifuged at 13,000× g for 10 min. The resulting supernatants were supplemented with
thiobarbituric acid (TBA) and were boiled at 95 ◦C in a water bath for 60 min. The MDA-TBA adduct
was formed, which was quantified colorimetrically at 532 nm. The amount of MDA in the samples
was detected by plotting against an MDA standard (provided in the kit) calibration curve. The values
were expressed as nmol/mg protein.
4.8. Measurement of SOD Activity and NO Production
Total superoxide dismutase (SOD) activity was measured using a commercially available
superoxide dismutase activity assay kit (ab65354, Abcam), as described previously [107]. Briefly,
distal colon tissues were homogenised in ice-cold Tris/HCl (0.1 M, pH 7.4) containing Triton X-100
(0.5%), β-mercaptoethanol (5 mM) and PMSF (phenylmethylsulfonyl fluoride) (0.1 mg/mL). After
centrifugation at 14,000× g for 5 min, supernatants (containing cytosolic and mitochondrial SOD
enzyme) were assayed by adding WST-1 (water soluble tetrazolium-1) solution according to the
manufacturer’s instructions. The data represents the percentage inhibition of superoxide production
by SOD and was termed the SOD activity. The more SOD in the samples, more its inhibitory activity.
For NO generation, a Griess reagent kit (G2930, Promega, Victoria, Australia) was used to measure
nitrite, a stable by-product of NO, as described previously [108]. Colon tissue explants and nitrite
standards (100, 50, 25, 12.5, 6.25, 3.13, 1.56 and 0 µM) were pipetted into a 96-well plate. The samples
and standards were incubated according to the manufacturer’s instructions. The detection was based
on the chemical reaction between sulphanilamide and N-1-napthylethylenediamine dihydrochloride
(NED) under acidic conditions. The sample absorbance was plotted against a nitrite standard reference
curve at 550 nm. The values were expressed as a concentration in µM/gram of tissue.
4.9. Cytokine Measurement from the Tissue Explant Culture
Proximal and distal colon samples were excised from the test animals, washed with PBS and
cultured in 12–well plates containing 500 µL/well of RPMI1640 (In Vitro Technologies Pty Ltd.,
Melbourne, Australia), supplemented with 10% Fetal Bovine Serum (Gibco, Life Technologies Pty Ltd.,
Melbourne, Australia) and 1% antibiotics solution (containing 10 mg/mL streptomycin and 10,000 U/mL
of penicillin; Sigma-Aldrich Pty Ltd., New south Wales, Australia), as mentioned previously [72]. After
incubating for 24 h, the supernatant was collected, centrifuged and analysed for cytokine detection.
The concentration of cytokines in the colonic tissue explant were measured using a Bio-Plex Pro Mouse
cytokine 23-plex kit (#M60009RDPD, Bio-Rad Laboratories, New South Wales, Australia) following the
manufacturer’s protocol in a Bio-Plex 200 instrument (Bio-Rad Laboratories), and were analysed using
the Bioplex Manager software, version 6 (Bio-Rad Laboratories). The cytokine levels were normalised
to the measured tissue weight (gram). The concentration of cytokines was presented as pg/mL/g
of tissue.
4.10. Statistical Analysis
GraphPad Prism software version 6.0 (GraphPad Software Ltd, La Jolla, California, United States
of America) was used to perform statistical analysis. Results were expressed as a mean ± SEM from
at least 3 to 10 animals per group. Statistical differences between the groups were evaluated using
one-way analysis of variance (ANOVA) followed by Tukey’s post-hoc. Two-way ANOVA followed
by Tukey’s post-hoc test was used to analyse DAI and body weight changes during the experimental
period. A statistical difference of p < 0.05 was considered significant.
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Figure S1: Effect of idebenone on the level of pro-inflammatory cytokines and chemokines in colon tissue. (A)
Tissue levels of IL-1β, INF-γ, IL-12p40, IL-12p70, MCP-1, IL-2, IL-5, IL-9 and IL-13 in the distal colon and (B) the
levels of IL-1α, IL-1β, INF-γ, G-CSF, MIP-1β, RANTES, IL-3, IL-12p40, IL-12p70, IL-10, IL-4 and IL-13 in proximal
colon were quantified using a Bio-Plex assay. Data are expressed as a mean ± SEM (n = 3/group) and statistical
significance was evaluated using one-way ANOVA followed by Tukey’s post-test, where * p < 0.05.
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